TelyRx Holdings Inc. has seen a remarkable surge in its stock price, gaining over 6% in just one day.
In the latest trading session, TelyRx Holdings Inc. (TELY.TO) closed up 6.22% at CA$2.56. This increase comes as the company reports rising revenues and more prescriptions filled, which could signal positive momentum for investors.
Investor takeaway: Investors should look at TelyRx's recent financial performance and growth in prescription fills as encouraging signs, though the company still faces challenges with net losses.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
TelyRx Holdings Inc.
TELY.TO
TELY.TO
TelyRx Holdings Inc.
WealthAwesomeMarket cap
$73.09M
52W high
$4.25
52W low
$2.00
1W change
+10.20%
Analyst Price Targets
Based on analyst covering TELY
Wall Street analysts forecast TELY stock price to rise 122.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+122.2% Upside
Current Price
C$2.70
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELY's historical volatility
30-Day Vol
102.6%
Annualized
90-Day Vol
97.8%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$2.26
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$2.54 | C$1.79 โ C$3.62 |
| 60 trading days | C$2.40 | C$1.45 โ C$3.95 |
| 90 trading days | C$2.26 | C$1.22 โ C$4.17 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
TelyRx's Stock Rises 6.22% in One Day
The stock's rise reflects growing investor confidence as TelyRx continues to expand its revenue and prescription metrics.
Bull case
The companyโs revenue grew from $6.9 million in Q1 2025 to $19.4 million in Q1 2026. This, along with a significant increase in prescriptions filled, suggests strong market demand for its products.
Bear case
Despite the revenue growth, TelyRx reported a net loss of $4.7 million in Q1 2026, raising concerns about its profitability and long-term financial stability.
Revenue Growth Signals Potential
TelyRx reported a remarkable increase in revenue, reaching $19.4 million in Q1 2026, compared to just $6.9 million in the same quarter last year. This growth is largely due to an increase in the number of prescriptions filled, which rose to 236,000 from 82,000 a year prior. Such metrics indicate strong demand for TelyRx's offerings and could attract further investor interest.
Challenges Ahead Despite Growth
While the revenue figures are promising, TelyRx's net loss of $4.7 million in Q1 2026 raises questions about its profitability. Investors should remain cautious, as the company needs to address its financial health to sustain long-term growth. The current trajectory suggests potential, but the path to profitability remains uncertain.
Advertisement
